Analyst Price Targets — VERX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 1:52 pm | — | D.A. Davidson | $13.00 | $12.32 | TheFly | Vertex price target lowered to $13 from $23 at DA Davidson |
| February 12, 2026 1:46 pm | — | BMO Capital | $16.00 | $12.79 | TheFly | Vertex price target lowered to $16 from $22 at BMO Capital |
| February 12, 2026 1:33 pm | Adam Hotchkiss | Goldman Sachs | $23.00 | $12.16 | TheFly | Vertex price target lowered to $23 from $25 at Goldman Sachs |
| February 12, 2026 1:16 pm | — | Morgan Stanley | $20.00 | $12.80 | TheFly | Vertex price target lowered to $20 from $33 at Morgan Stanley |
| February 12, 2026 11:44 am | — | UBS | $25.00 | $12.83 | TheFly | Vertex price target lowered to $25 from $37 at Citizens |
| February 11, 2026 9:42 pm | — | Jefferies | $16.00 | $12.83 | TheFly | Vertex downgraded to Hold from Buy at Jefferies |
| February 11, 2026 6:07 pm | — | Stifel Nicolaus | $16.00 | $12.78 | TheFly | Vertex price target lowered to $16 from $23 at Stifel |
| February 11, 2026 6:04 pm | Joshua Reilly | Needham | $20.00 | $12.83 | StreetInsider | Vertex Inc. (VERX) PT Lowered to $20 at Needham |
| February 2, 2026 9:07 pm | — | Piper Sandler | $20.00 | $18.70 | TheFly | Vertex downgraded to Neutral from Overweight at Piper Sandler |
| January 14, 2026 11:43 am | — | Goldman Sachs | $25.00 | $19.73 | TheFly | Vertex price target lowered to $25 from $28 at Goldman Sachs |
Latest News for VERX
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET. Susie Lisa, Senior Vice President,…
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the…
Vertex, Inc. (VERX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Banco Santander S.A. lessened its holdings in shares of Vertex, Inc. (NASDAQ: VERX) by 47.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 177,826 shares of the company's stock after selling 160,174 shares during the quarter. Banco Santander S.A.
KING OF PRUSSIA, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX), a global provider of tax technology solutions, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at two upcoming conferences.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VERX.
U.S. House Trading
No House trades found for VERX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.